摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 3-(2,4,5-trifluorophenyl)-6,7-dihydro-1H-pyrazolo[4,3-b]pyridine-4(5H)-carboxylate | 1231908-43-2

中文名称
——
中文别名
——
英文名称
tert-butyl 3-(2,4,5-trifluorophenyl)-6,7-dihydro-1H-pyrazolo[4,3-b]pyridine-4(5H)-carboxylate
英文别名
Tert-butyl 3-(2,4,5-trifluorophenyl)-1,5,6,7-tetrahydropyrazolo[4,3-b]pyridine-4-carboxylate
tert-butyl 3-(2,4,5-trifluorophenyl)-6,7-dihydro-1H-pyrazolo[4,3-b]pyridine-4(5H)-carboxylate化学式
CAS
1231908-43-2
化学式
C17H18F3N3O2
mdl
——
分子量
353.344
InChiKey
DJWYXUZZVZZBJD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    58.2
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • BICYCLIC PYRAZOLO-HETEROCYCLES
    申请人:Luo Robert Zhiyong
    公开号:US20110144121A1
    公开(公告)日:2011-06-16
    The present invention provides substituted pyrazolo-heterocycles having the general structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.
    本发明提供了具有一般式I的取代吡唑杂环化合物,还提供了公认的药用盐、酸盐、合物、溶剂合物和化合物I的立体异构体。这些化合物可用于调节大麻素受体,并用于预防和治疗与大麻素受体相关的疾病和病况,例如疼痛、炎症和瘙痒。
  • US7741350B1
    申请人:——
    公开号:US7741350B1
    公开(公告)日:2010-06-22
  • US8211926B2
    申请人:——
    公开号:US8211926B2
    公开(公告)日:2012-07-03
  • US8653127B2
    申请人:——
    公开号:US8653127B2
    公开(公告)日:2014-02-18
  • [EN] BICYCLIC PYRAZOLO-HETEROCYCLES<br/>[FR] HÉTÉROCYCLES PYRAZOLO BICYCLIQUES
    申请人:CARA THERAPEUTICS INC
    公开号:WO2010088050A2
    公开(公告)日:2010-08-05
    The present invention provides substituted pyrazolo-heterocycles having the general structure of formula I (I). The structures of rings A and B and substituents Ra, Rb and Rc are described in the specification. Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis, treatment and inhibition of cannabinoid receptor- associated diseases and conditions, such as pain, inflammation and pruritis.
查看更多